Literature DB >> 33017355

Hard signs gone soft: A critical evaluation of presenting signs of extremity vascular injury.

Anna Noel Romagnoli1, Joseph DuBose, Anahita Dua, Richard Betzold, Tiffany Bee, Timothy Fabian, Jonathan Morrison, David Skarupa, Jeanette Podbielski, Kenji Inaba, David Feliciano, David Kauvar.   

Abstract

BACKGROUND: Despite advances in management of extremity vascular injuries, "hard signs" remain the primary criterion to determine need for imaging and urgency of exploration. We propose that hard signs are outdated and that hemorrhagic and ischemic signs of vascular injury may be of greater clinical utility.
METHODS: Extremity arterial injuries from the American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment registry were analyzed to examine the relationships between hard signs, ischemic signs, and hemorrhagic signs of extremity vascular injury with workup, diagnosis, and management.
RESULTS: Of 1,910 cases, 1,108 (58%) had hard signs of vascular injury. Computed tomography angiography (CTA) was more commonly used as the diagnostic modality in patients without hard signs, while operative exploration was primarily used for diagnosis in hard signs. Patients undergoing CTA were more likely to undergo endovascular or hybrid repair (EHR) (10.7%) compared with patients who underwent exploration for diagnosis (1.5%). Of 915 patients presenting with hemorrhagic signs, CTA was performed 14.5% of the time and was associated with a higher rate of EHR and observation. Of the 490 patients presenting with ischemic signs, CTA was performed 31.6% of the time and was associated with higher rates of EHR and observation. Hemorrhagic signs were associated with arterial transection, while ischemic signs were associated with arterial occlusion. Patients with ischemic signs undergoing exploration for diagnosis received more units of packed red blood cells during the first 24 hours. There was no difference in amputation rate, reintervention rate, hospital length of stay, or mortality in comparing groups who underwent CTA versus exploration.
CONCLUSION: Hard signs have limitations in identification and characterization of extremity arterial injuries. A strategy of using hemorrhagic and ischemic signs of vascular injury is of greater clinical utility. Further prospective study is needed to validate this proposed redefinition of categorization of presentations of extremity arterial injury. LEVEL OF EVIDENCE: Diagnostic, level III.
Copyright © 2020 American Association for the Surgery of Trauma.

Entities:  

Year:  2021        PMID: 33017355     DOI: 10.1097/TA.0000000000002958

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  5 in total

Review 1.  Limb Salvage Versus Amputation for the Mangled Extremity: Factors Affecting Decision-Making and Outcomes.

Authors:  Isaac Okereke; Elsenosy Abdelfatah
Journal:  Cureus       Date:  2022-08-18

2.  A swine model of reproducible timed induction of peripheral arterial shunt failure: Developing warning signs of imminent shunt failure.

Authors:  David P Stonko; Neerav Patel; Joseph Edwards; Hossam Abdou; Eric Lang; Noha N Elansary; Rebecca Treffalls; Joseph White; Jonathan J Morrison
Journal:  JVS Vasc Sci       Date:  2022-08-17

3.  Imaging in extremity vascular trauma: can MDCT angiography predict the nature of injury?

Authors:  Deeksha Bhalla; Atin Kumar; Shivanand Gamanagatti; Sushma Sagar; Subodh Kumar; Amit Gupta
Journal:  Emerg Radiol       Date:  2022-04-25

4.  Computed tomography angiography is associated with low added utility for detecting clinically relevant vascular injuries among patients with extremity trauma.

Authors:  Riley Brian; Daniel J Bennett; Woon Cho Kim; Deborah M Stein
Journal:  Trauma Surg Acute Care Open       Date:  2021-12-20

5.  Traumatic proximal brachial artery injury selectively managed non-operatively: A case report and review of the literature.

Authors:  Allyson M Hynes
Journal:  Trauma Case Rep       Date:  2022-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.